Case Study
Tuesday, October 07
09:20 AM - 09:45 AM
Live in Berlin
Less Details
The presentation addresses the main challenges and the best approaches of in-depth comparative analysis of market access for breast cancer therapies, focusing on the Netherlands and benchmarking against several other countries. The research highlights critical differences in access timelines, and availability of innovative treatments. By mapping the breast cancer landscape in the Netherlands—including product availability and clinical research activity—the study identifies gaps and opportunities for accelerating patient access. In this session, you will learn:
Henriette Burghoorn is an experienced Associate Director of Market Access at Gilead Sciences, with a strong track record in the biotechnology industry. She has extensive expertise in reimbursement strategies across a broad range of therapeutic areas, including liver disease, HIV, oncology, hematology, cardiovascular, and diabetes indications. Henriette is known for her strategic insight and dedication to improving patient access to innovative treatments.
The Pop in Your Job
My passion in my work is on improving patients’ lives and making access to innovative medicins available for those patients in need. In the process of gaining access, I love transforming complex processes into intelligent, solutions that truly make an impact.